Patent US4609548A successfully refreshed from Google Patents.
US4609548A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Vaccines for pseudorabies disease and methods for use of same
Assignee: Baylor College of Medicine
•
Filing: 1984-12-20
•
Granted: 1986-09-02
•
Expires: 2004-12-20
Abstract
Abstract Temperature-resistant pseudorabies viruses which fail to produce any functional TK as a result of mutagen-induced mutation and temperature-resistant pseudorabies viruses which fail to produce any functional TK as a result of a deletion in the tk gene, vaccines containing same, methods for production of same and methods for use of same.
Inventors
- 👤 Malon Kit
- 👤 Saul Kit
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 13:28
CPC Classifications
C; C12; C12N; C12N15/00; A; A61; A61K; A61K39/00; A61K39/12; A61K39/245; A61P; A61P43/00; A61K2039/51; A61K2039/525; A61K2039/5254; C12N2710/00; C12N2710/00011; C12N2710/16011; C12N2710/16711; C12N2710/16734; Y; Y10; Y10S; Y10S424/00; Y10S424/822
Claims Analysis
Total Claims: 134
Claim 1
Independent Claim
39 words
A modified live virus vaccine for pseudorabies disease comprising: (1) pharmaceutically effective amount of a temperature-resistant pseudorabies virus which fails to produce any functional TK as a result of mutagen-induced mutation; and (2) a pharmaceutically acceptable carrier or diluent.
Claim 2
Dependent Claim
39 words
A modified live virus vaccine for pseudorabies disease comprising: (1) pharmaceutically effective amount of a temperature-resistant pseudorabies virus which fails to produce any functional TK as a result of mutagen-induced mutation; and (2) a pharmaceutically acceptable carrier or diluent.
Claim 3
Dependent Claim
23 words
The modified live virus vaccine for pseudorabies disease as in claim 1, wherein said virus has the characteristics of PRV(BUK-5A) (ATCC No. VR-2078).
Claim 4
Dependent Claim
17 words
The modified live virus vaccine for pseudorabies disease as in claim 1, wherein said virus is lypholized.
Claim 5
Dependent Claim
37 words
The modified live virus vaccine for pseudorabies disease as in claim 1 wherein said pharmaceutically acceptable carrier or diluent is physiological buffered medium containing from about 2.5 to 15% serum which does not contain antibodies to PRV.
Claim 6
Dependent Claim
34 words
The modified live virus vaccine for pseudorabies disease as in claim 4, wherein said serum is selected from the group consisting of swine serum, calf serum, fetal calf serum, horse serum and lamb serum.
Claim 7
Dependent Claim
31 words
The modified live virus vaccine for pseudorabies disease as in claim 1, wherein said pharmaceutically acceptable carrier or diluent is physiological buffered medium containing from about 0.5 to 3.0% serum protein.
Claim 8
Dependent Claim
30 words
The modified live virus vaccine for pseudorabies disease as in claim 6, wherein said serum protein is selected from the group consisting of porcine serum albumin and bovine serum albumin.
Claim 9
Dependent Claim
24 words
The modified live virus vaccine for pseudorabies disease as in claim 1, wherein said pharmaceutically effective is about 10 5 to 5×10 8 p.f.u.
Claim 10
Dependent Claim
25 words
The modified live virus vaccine for pseudorabies disease as in claim 8, wherein said pharmaceutically effective amount is about 10 6 to 10 7 p.f.u.
Claim 11
Dependent Claim
214 words
A modified live-virus vaccine for pseudorabies disease comprising: (1) a pharmaceutically effective amount of a temperature-resistant pseudorabies virus which fails to produce any functional TK as a result of mutagen-induced mutation produced by the process comprising: (a) plaque-purifying a PRV tk + strain in tk - host cells at a permissive temperature for a temperature-sensitive virus; (b) propagating the resulting virus of step (a) in tk - host cells 2 to 5 times in the presence of a mutagen at a temperature permissive for a temperature-sensitive virus; (c) propagating the resulting virus of step (b) in tk + host cells in the presence of a mutagen at a non-permissive temperature for a temperature-sensitive virus; (d) propagating the resulting virus of step (c) in tk + host cells in the presence of a mutagen at a permissive temperature for a temperature-sensitive virus; (e) propagating the resulting virus of step (d) in tk + host cells in the presence of a selective agent at a permissive temperature for a temperature-sensitive virus; and (f) propagating the resulting virus of step (e) in tk + host cells in the presence of a mutagen at a permissive temperature for a temperature-sensitive virus to produce a temperature-resistance PRV tk - mutagen-induced mutant; and (2) a pharmaceutically acceptable carrier or diluent.
Claim 12
Dependent Claim
214 words
A modified live-virus vaccine for pseudorabies disease comprising: (1) a pharmaceutically effective amount of a temperature-resistant pseudorabies virus which fails to produce any functional TK as a result of mutagen-induced mutation produced by the process comprising: (a) plaque-purifying a PRV tk + strain in tk - host cells at a permissive temperature for a temperature-sensitive virus; (b) propagating the resulting virus of step (a) in tk - host cells 2 to 5 times in the presence of a mutagen at a temperature permissive for a temperature-sensitive virus; (c) propagating the resulting virus of step (b) in tk + host cells in the presence of a mutagen at a non-permissive temperature for a temperature-sensitive virus; (d) propagating the resulting virus of step (c) in tk + host cells in the presence of a mutagen at a permissive temperature for a temperature-sensitive virus; (e) propagating the resulting virus of step (d) in tk + host cells in the presence of a selective agent at a permissive temperature for a temperature-sensitive virus; and (f) propagating the resulting virus of step (e) in tk + host cells in the presence of a mutagen at a permissive temperature for a temperature-sensitive virus to produce a temperature-resistance PRV tk - mutagen-induced mutant; and (2) a pharmaceutically acceptable carrier or diluent.
Claim 13
Dependent Claim
24 words
The modified live virus vaccine for pseudorabies disease as in claim 10, wherein said virus has the identifying characteristics of PRV(BUK-5A) (ATCC No. VR-2078).
Claim 14
Dependent Claim
17 words
The modified live virus vaccine for pseudorabies disease as in claim 10, wherein said virus is lypholized.
Claim 15
Dependent Claim
37 words
The modified live virus vaccine for pseudorabies disease as in claim 10, wherein said pharmaceutically acceptable carrier or diluent is physiological buffered medium containing from about 2.5 to 15% serum which does not contain antibodies to PRV.
Claim 16
Dependent Claim
34 words
The modified live virus vaccine for pseudorabies disease as in claim 13, wherein said serum is selected from the group consisting of swine serum, calf serum, fetal calf serum, horse serum and lamb serum.
Claim 17
Dependent Claim
31 words
The modified live virus vaccine for pseudorabies disease as in claim 10, wherein said pharmaceutically acceptable carrier or diluent is physiological buffered medium containing from about 0.5 to 3.0% serum protein.
Claim 18
Dependent Claim
30 words
The modified live virus vaccine for pseudorabies disease as in claim 5, wherein said serum protein is selected from the group consisting of porcine serum albumin and bovine serum albumin.
Claim 19
Dependent Claim
25 words
The modified live virus vaccine for pseudorabies disease as in claim 10, wherein said pharmaceutically effective amount is about 10 5 to 5×10 8 p.f.u.
Claim 20
Dependent Claim
25 words
The modified live virus vaccine for pseudorabies disease as in claim 17, wherein said pharmaceutically effective amount is about 10 6 to 10 7 p.f.u.
Claim 21
Dependent Claim
51 words
The modified live virus vaccine for pseudorabies disease as in claim 10, wherein said PRV tk + strain is selected from the group consisting of PRV(BUK) strain, SUCH-1 strain, K strain, Norden strain, PRV(Auj) strain, P-2208 strain, KC-152D strain, S62/26 Iowa strain, IND-FH strain, IND-S strain, IND-R strain and Shope strain.
Claim 22
Dependent Claim
21 words
The modified live virus vaccine for pseudorabies disease as in claim 19, wherein said PRV tk + strain is PRV(BUK) strain.
Claim 23
Dependent Claim
26 words
The modified live virus vaccine for pseudorabies disease as in claim 10, wherein said permissive temperature for a temperature-sensitive virus is about 33° to 37.5° C.
Claim 24
Dependent Claim
23 words
The modified live virus vaccine for pseudorabies disease as in claim 21, wherein said permissive temperature for a temperature-sensitive virus is 34.5° C.
Claim 25
Dependent Claim
26 words
The modified live virus vaccine for pseudorabies disease as in claim 10, wherein said non-permissive temperature for a temperature-sensitive virus is about 38.5° to 40° C.
Claim 26
Dependent Claim
23 words
The modified live virus vaccine for pseudorabies disease as in claim 23, wherein said non-permissive temperature for a temperature-sensitive virus is 39.1° C.
Claim 27
Dependent Claim
44 words
The modified live virus vaccine for pseudorabies disease as in claim 10, wherein said tk - host cells are selected from the group consisting of rabbit Rab(BU), mouse LM(TK - ), human HeLa(BU25), syrain hamster BHK 21 (TK - ) and human line 143.
Claim 28
Dependent Claim
21 words
The modified live virus vaccine for pseudorabies disease as in claim 25, wherein said tk - host cells are rabbit Rab(BU).
Claim 29
Dependent Claim
47 words
The modified live virus vaccine for pseudorabies disease as in claim 10, wherein said tk + host cells are selected from the group consisting of Rab-9, primary rabbit kidney cells, secondary rabbit kidney cells, monkey cells, human cells, human embryonic kidney cells and chick embryo fibroblast cells.
Claim 30
Dependent Claim
20 words
The modified live virus vaccine for pseudorabies disease as in claim 27, wherein said tk + host cells are Rab-9.
Claim 31
Dependent Claim
31 words
The modified live virus vaccine for pseudorabies disease as in claim 10, wherein said mutagen is selected from the group consisting of BrdUrd, NH 2 OH, HONO, nitrosoguanidine and UV light.
Claim 32
Dependent Claim
17 words
The modified live virus vaccine for pseudorabies disease as in claim 29, wherein said mutagen is BrdUrd.
Claim 33
Dependent Claim
29 words
The modified live virus vaccine for pseudorabies disease as in claim 10, wherein said selective agent is selected from the group consisting of BrdUrd, araT, BVDU, FMAU and AIdUrd.
Claim 34
Dependent Claim
18 words
The modified live virus vaccine for pseudorabies disease as in claim 31, wherein said selective agent is araT.
Claim 35
Independent Claim
36 words
A method of immunizing an animal against pseudorabies disease comprising administering a pharmaceutically effective amount of a temperature-resistant pseudorabies virus which falls to produce any functional TK as a result of mutagen-induced mutation, to an animal.
Claim 36
Independent Claim
36 words
A method of immunizing an animal against pseudorabies disease comprising administering a pharmaceutically effective amount of a temperature-resistant pseudorabies virus which falls to produce any functional TK as a result of mutagen-induced mutation, to an animal.
Claim 37
Dependent Claim
25 words
The method of immunizing an animal against pseudorabies disease as in claim 33, wherein said virus has the identifying characteristics of PRV(BUK-5A) (ATCC No. VR-2078).
Claim 38
Dependent Claim
22 words
The method of immunizing an animal against pseudorabies disease as in claim 33, wherein said administering is conducted intranasally, intramuscularly or subcutaneously.
Claim 39
Dependent Claim
19 words
The method of immunizing an animal against pseudorabies disease as in claim 35, wherein said administering is conducted intramuscularly.
Claim 40
Dependent Claim
26 words
The method of immunizing an animal against pseudorabies disease as in claim 33, wherein said pharmaceutically effective amount is about 10 5 to 5×10 8 p.f.u.
Claim 41
Dependent Claim
26 words
The method of immunizing an animal against pseudorabies disease as in claim 37, wherein said pharmaceutically effective amount is about 10 6 to 10 7 p.f.u.
Claim 42
Dependent Claim
28 words
The method of immunizing an animal against pseudorabies disease as in claim 33, wherein said animal is selected from the group consisting of swine, goats, sheep and cattle.
Claim 43
Dependent Claim
18 words
The method of immunizing an animal against pseudorabies disease as in claim 39, wherein said animal is swine.
Claim 44
Dependent Claim
18 words
The method of immunizing an animal against pseudorabies disease as in claim 39, wherein said animal is cattle.
Claim 45
Independent Claim
212 words
A method of immunizing an animal against pseudorabies disease comprising administering a pharmaceutically acceptable amount of a temperature-resistant pseudorabies virus which fails to produce any functional TK as a result of a mutagen-induced mutation produced by a process comprising: (1) plaque-purifying a PRV tk + strain in tk - host cells at a permissive temperature for a temperature-sensitive virus; (2) propagating the resulting virus of step (1) in tk - host cells 2 to 5 times in the presence of a mutagen at a permissive temperature for a temperature-sensitive virus; (3) propagating the resulting virus of step (2) in tk + host cells in the presence of a mutagen at a non-permissive temperature for a temperature-sensitive virus; (4) propagating the resulting virus of step (3) in tk + host cells in the presence of a mutagen at a permissive temperature for a temperature-sensitive virus; (5) propagating the resulting virus of step (4) in tk + host cells in the presence of a selective agent at a permissive temperature for a temperature-sensitive virus; and (6) propagating the resulting virus of step (5) in tk + host cells in the presence of a mutagen at a permissive temperature for a temperature-sensitive virus to produce a temperature-resistant PRV tk - mutagen-induced mutant, to an animal.
Claim 46
Independent Claim
212 words
A method of immunizing an animal against pseudorabies disease comprising administering a pharmaceutically acceptable amount of a temperature-resistant pseudorabies virus which fails to produce any functional TK as a result of a mutagen-induced mutation produced by a process comprising: (1) plaque-purifying a PRV tk + strain in tk - host cells at a permissive temperature for a temperature-sensitive virus; (2) propagating the resulting virus of step (1) in tk - host cells 2 to 5 times in the presence of a mutagen at a permissive temperature for a temperature-sensitive virus; (3) propagating the resulting virus of step (2) in tk + host cells in the presence of a mutagen at a non-permissive temperature for a temperature-sensitive virus; (4) propagating the resulting virus of step (3) in tk + host cells in the presence of a mutagen at a permissive temperature for a temperature-sensitive virus; (5) propagating the resulting virus of step (4) in tk + host cells in the presence of a selective agent at a permissive temperature for a temperature-sensitive virus; and (6) propagating the resulting virus of step (5) in tk + host cells in the presence of a mutagen at a permissive temperature for a temperature-sensitive virus to produce a temperature-resistant PRV tk - mutagen-induced mutant, to an animal.
Claim 47
Dependent Claim
24 words
The method of immunizing an animal against pseudorabies disease as in claim 42, wherein said virus has the characteristics of PRV(BUK-5A) (ATCC No. VR-2078).
Claim 48
Dependent Claim
52 words
The method of immunizing an animal against pseudorabies disease as in claim 42, wherein said PRV tk + strain is selected from the group consisting of PRV(BUK) strain, SUCH-1 strain, K strain, Norden strain, PRV(Auj) strain, P-2208 strain, KC-152D strain, S62/26 Iowa strain, IND-FH strain, IND-S strain, IND-R strain and Shope strain.
Claim 49
Dependent Claim
22 words
The method of immunizing an animal against pseudorabies disease as in claim 44, wherein said PRV tk + strain is PRV(BUK) strain.
Claim 50
Dependent Claim
27 words
The method of immunizing an animal against pseudorabies disease as in claim 42, wherein said permissive temperature for a temperature-sensitive virus is about 33° to 37.5° C.
Claim 51
Dependent Claim
24 words
The method of immunizing an animal against pseudorabies disease as in claim 46, wherein said permissive temperature for a temperature-sensitive virus is 34.5° C.
Claim 52
Dependent Claim
27 words
The method of immunizing an animal against pseudorabies disease as in claim 42, wherein said non-permissive temperature for a temperature-sensitive virus is about 38.5° to 40° C.
Claim 53
Dependent Claim
24 words
The method of immunizing an animal against pseudorabies disease as in claim 48, wherein said non-permissive temperature for a temperature-sensitive virus is 39.1° C.
Claim 54
Dependent Claim
45 words
The method of immunizing an animal against pseudorabies disease as in claim 42, wherein said tk - host cells are selected from the group consisting of rabbit Rab(BU), mouse LM(TK - ), human HeLa(BU25), syrian hamster BHK 21 (TK - ) and human line 143.
Claim 55
Dependent Claim
22 words
The method of immunizing an animal against pseudorabies disease as in claim 50, wherein said tk - host cells are rabbit Rab(BU).
Claim 56
Dependent Claim
48 words
The method of immunizing an animal against pseudorabies disease as in claim 42, wherein said tk + host cells are selected from the group consisting of Rab-9, primary rabbit kidney cells, secondary rabbit kidney cells, monkey cells, human cells, human embryonic kidney cells and chick embryo fibroblast cells.
Claim 57
Dependent Claim
21 words
The method of immunizing an animal against pseudorabies disease as in claim 52, wherein said tk + host cells are Rab-9.
Claim 58
Dependent Claim
32 words
The method of immunizing an animal against pseudorabies disease as in claim 42, wherein said mutagen is selected from the group consisting of BrdUrd, NH 2 OH, HONO, nitrosoguanidine and UV light.
Claim 59
Dependent Claim
18 words
The method of immunizing an animal against pseudorabies disease as in claim 54, wherein said mutagen is BrdUrd.
Claim 60
Dependent Claim
30 words
The method of immunizing an animal against pseudorabies disease as in claim 42, wherein said selective agent is selected from the group consisting of BrdUrd, araT, BVDU, FMAU and AIdUrd.
Claim 61
Dependent Claim
19 words
The method of immunizing an animal against pseudorabies disease as in claim 56, wherein said selective agent is araT.
Claim 62
Dependent Claim
22 words
The method of immunizing an animal against pseudorabies disease as in claim 42, wherein said administering is conducted intranasally, intramuscularly or subcutaneously.
Claim 63
Dependent Claim
19 words
The method of immunizing an animal against pseudorabies disease as in claim 58, wherein said administering is conducted intramuscularly.
Claim 64
Dependent Claim
26 words
The method of immunizing an animal against pseudorabies disease as in claim 42, wherein said pharmaceutically effective amount is about 10 5 to 5×10 8 p.f.u.
Claim 65
Dependent Claim
26 words
The method of immunizing an animal against pseudorabies disease as in claim 40, wherein said pharmaceutically effective amount is about 10 6 to 10 7 p.f.u.
Claim 66
Dependent Claim
28 words
The method of immunizing an animal against pseudorabies disease as in claim 42, wherein said animal is selected from the group consisting of swine, goats, sheep and cattle.
Claim 67
Dependent Claim
18 words
The method of immunizing an animal against pseudorabies disease as in claim 62, wherein said animal is swine.
Claim 68
Dependent Claim
18 words
The method of immunizing an animal against pseudorabies disease as in claim 62, wherein said animal is cattle.
Claim 69
Dependent Claim
44 words
A modified live virus vaccine for pseudorabies disease comprising: (1) a pharmaceutically acceptable amount of a temperature-resistant pseudorabies virus which fails to produce any functional TK as a result of a deletion in the tk gene; and (2) a pharmaceutically acceptable carrier or diluent.
Claim 70
Dependent Claim
44 words
A modified live virus vaccine for pseudorabies disease comprising: (1) a pharmaceutically acceptable amount of a temperature-resistant pseudorabies virus which fails to produce any functional TK as a result of a deletion in the tk gene; and (2) a pharmaceutically acceptable carrier or diluent.
Claim 71
Dependent Claim
23 words
The modified live virus vaccine for pseudorabies disease as in claim 65, wherein said deletion is about 10 to 1500 bp in size.
Claim 72
Dependent Claim
23 words
The modified live virus vaccine for pseudorabies disease as in claim 66, wherein said deletion is about 75 to 750 bp in size.
Claim 73
Dependent Claim
25 words
The modified live virus vaccine for pseudorabies disease as in claim 65, wherein said virus has the identifying characteristics of PRV(BUK-dl 3) (ATCC No. VR-2074).
Claim 74
Dependent Claim
17 words
The modified live virus vaccine for pseudorabies disease as in claim 65, wherein said virus is lypholized.
Claim 75
Dependent Claim
37 words
The modified live virus vaccine for pseudorabies disease as in claim 65, wherein said pharmaceutically acceptable carrier or diluent is physiological buffered medium containing from about 2.5 to 15% serum which does not contain antibodies to PRV.
Claim 76
Dependent Claim
34 words
The modified live virus vaccine for pseudorabies disease as in claim 70, wherein said serum is selected from the group consisting of swine serum, calf serum, fetal calf serum, horse serum and lamb serum.
Claim 77
Dependent Claim
31 words
The modified live virus vaccine for pseudorabies disease as in claim 65, wherein said pharmaceutically acceptable carrier or diluent is physiological buffered medium containing from about 0.5 to 3.0% serum protein.
Claim 78
Dependent Claim
30 words
The modified live virus vaccine for pseudorabies disease as in claim 72, wherein said serum protein is selected from the group consisting of porcine serum albumin and bovine serum albumin.
Claim 79
Dependent Claim
25 words
The modified live virus vaccine for pseudorabies disease as in claim 65, wherein said pharmaceutically effective amount is about 10 5 to 5×10 8 p.f.u.
Claim 80
Dependent Claim
25 words
The modified live virus vaccine for pseudorabies disease as in claim 74, wherein said pharmaceutically effective amount is about 10 6 to 10 7 p.f.u.
Claim 81
Dependent Claim
204 words
A modified live virus vaccine for pseudorabies disease comprising: (1) a pharmaceutically acceptable amount of a temperature-resistant virus which fails to produce any functional TK as a result of a deletion in the tk gene produced by a process comprising: (a) contructing a hybrid plasmid comprising a cloning vector and a DNA fragment of PRV containing substantially all of the PRV tk gene; (b) co-transfecting, in tk + host cells, the hybrid plasmid of step (a) with DNA from a temperature-resistant PRV tk - mutagen-induced mutant; (c) selecting, in tk - host cells, for PRV tk + from the virus produced in step (b); (d) deleting DNA sequences from the hybrid plasmid of step (a) such that less than substantially all of the PRV tk gene is present, while retaining PRV DNA sequences adjacent to each side of the deletion; (e) co-transfecting, in tk + host cells, PRV tk + DNA derived from the PRV tk + obtained in step (c) with the resulting hybrid plasmid of step (d); and (f) selecting, in tk - host cells, for PRV tk - from the virus produced in step (e) to produce temperature-resistant PRV tk - deletion mutants; and (2) a pharmaceutically acceptable carrier or diluent.
Claim 82
Dependent Claim
204 words
A modified live virus vaccine for pseudorabies disease comprising: (1) a pharmaceutically acceptable amount of a temperature-resistant virus which fails to produce any functional TK as a result of a deletion in the tk gene produced by a process comprising: (a) contructing a hybrid plasmid comprising a cloning vector and a DNA fragment of PRV containing substantially all of the PRV tk gene; (b) co-transfecting, in tk + host cells, the hybrid plasmid of step (a) with DNA from a temperature-resistant PRV tk - mutagen-induced mutant; (c) selecting, in tk - host cells, for PRV tk + from the virus produced in step (b); (d) deleting DNA sequences from the hybrid plasmid of step (a) such that less than substantially all of the PRV tk gene is present, while retaining PRV DNA sequences adjacent to each side of the deletion; (e) co-transfecting, in tk + host cells, PRV tk + DNA derived from the PRV tk + obtained in step (c) with the resulting hybrid plasmid of step (d); and (f) selecting, in tk - host cells, for PRV tk - from the virus produced in step (e) to produce temperature-resistant PRV tk - deletion mutants; and (2) a pharmaceutically acceptable carrier or diluent.
Claim 83
Dependent Claim
23 words
The modified live virus vaccine for pseudorabies disease as in claim 76, wherein said deletion is about 10 to 1500 bp in size.
Claim 84
Dependent Claim
23 words
The modified live virus vaccine for pseudorabies disease as in claim 77, wherein said deletion is about 75 to 750 bp in size.
Claim 85
Dependent Claim
25 words
The modified live virus vaccine for pseudorabies disease as in claim 76, wherein said virus has the identifying characteristics of PRV(BUK-dl 3) (ATCC No. VR-2074).
Claim 86
Dependent Claim
17 words
The modified live virus vaccine for pseudorabies disease as in claim 76, wherein said virus is lypholized.
Claim 87
Dependent Claim
39 words
The modified live virus vaccine for pseudorabies disease as in claim 76, wherein said cloning vector is selected from the group consisting of pBR322, pMB9, pBR325, pKH47, pBR328, pHC79, phage Charon 28, pKB11, pKSV-10, pMAR420 and oligo (dG)-tailed pBR322.
Claim 88
Dependent Claim
18 words
The modified live virus vaccine for pseudorabies disease as in claim 81, wherein said cloning vector is pBR322.
Claim 89
Dependent Claim
21 words
The modified live virus vaccine for pseudorabies disease as in claim 76, wherein said hybrid plasmid of step (a) is pBB-11.
Claim 90
Dependent Claim
32 words
The modified live virus vaccine for pseudorabies disease as in claim 76, wherein the PRV DNA sequences adjacent to each side of the deletion are at least about 400 bp in size.
Claim 91
Dependent Claim
24 words
The modified live virus vaccine for pseudorabies disease as in claim 76, wherein the resulting hybrid plasmid of step (d) is pBB-11 dl SacA26.
Claim 92
Dependent Claim
25 words
The modified live virus vaccine for pseudorabies disease as in claim 76, wherein said temperature-resistant PRV tk - mutagen-induced mutant is PRV(BUK-5A) (ATCC No. VR-2078).
Claim 93
Dependent Claim
25 words
The modified live virus vaccine for pseudorabies disease as in claim 76, wherein said PRV tk + DNA of step (e) is derived from PRV(BUK-5A-R1).
Claim 94
Dependent Claim
46 words
The modified live virus vaccine for pseudorabies as in claim 76, wherein said tk + host cells are selected from the group consisting of Rab-9, primary rabbit kidney cells, secondary rabbit kidney cells, monkey cells, human cells, human embryonic kidney cells and chick embryo fibroblast cells.
Claim 95
Dependent Claim
19 words
The modified live virus vaccine for pseudorabies as in claim 88, wherein said tk + host cells are Rab-9.
Claim 96
Dependent Claim
36 words
The modified live virus vaccine for pseudorabies as in claim 76, wherein said pharmaceutically acceptable carrier or diluent is physiological buffered medium containing from about 2.5 to 15% serum which does not contain antibodies to PRV.
Claim 97
Dependent Claim
33 words
The modified live virus vaccine for pseudorabies as in claim 90, wherein said serum is selected from the group consisting of swine serum, calf serum, fetal calf serum, horse serum and lamb serum.
Claim 98
Dependent Claim
31 words
The modified liver virus vaccine for pseudorabies disease as in claim 76, wherein said pharmaceutically acceptable carrier or diluent is physiological buffered medium containing from about 0.5 to 3.0% serum protein.
Claim 99
Dependent Claim
30 words
The modified live virus vaccine for pseudorabies disease as in claim 92, wherein said serum protein is selected from the group consisting of porcine serum albumin and bovine serum albumin.
Claim 100
Dependent Claim
25 words
The modified live virus vaccine for pseudorabies disease as in claim 76, wherein said pharmaceutically effective amount is about 10 5 to 5×10 8 p.f.u.
Claim 101
Dependent Claim
25 words
The modified live virus vaccine for pseudorabies disease as in claim 94, wherein said pharmaceutically effective amount is about 10 6 to 10 7 p.f.u.
Claim 102
Independent Claim
40 words
A method of immunizing an animal against pseudorabies disease comprising administering a pharmaceutically effective amount of a temperature-resistant pseudorabies virus which fails to produce any functional TK as a result of a deletion in the tk gene, to an animal.
Claim 103
Independent Claim
40 words
A method of immunizing an animal against pseudorabies disease comprising administering a pharmaceutically effective amount of a temperature-resistant pseudorabies virus which fails to produce any functional TK as a result of a deletion in the tk gene, to an animal.
Claim 104
Dependent Claim
24 words
The method of immunizing an animal against pseudorabies disease as in claim 96, wherein said deletion is about 10 to 1500 bp in size.
Claim 105
Dependent Claim
24 words
The method of immunizing an animal against pseudorabies disease as in claim 97, wherein said deletion is about 75 to 750 bp in size.
Claim 106
Dependent Claim
26 words
The method of immunizing an animal against pseudorabies disease as in claim 96, wherein said virus has the identifying characteristics of PRV(BUK-dl 3) (ATCC No. VR-2074).
Claim 107
Dependent Claim
22 words
The method of immunizing an animal against pseudorabies disease as in claim 96, wherein said administering is conducted intranasally, intramuscularly or subcutaneously.
Claim 108
Dependent Claim
20 words
The method of immunizing an animal against pseudorabies disease as in claim 100, wherein said means of administration is intramuscularly.
Claim 109
Dependent Claim
26 words
The method of immunizing an animal against pseudorabies disease as in claim 96, wherein said pharmaceutically effective amount is about 10 5 to 5×10 8 p.f.u.
Claim 110
Dependent Claim
26 words
The method of immunizing an animal against pseudorabies disease as in claim 102, wherein said pharmaceutically effective amount is about 10 6 to 10 7 p.f.u./ml.
Claim 111
Dependent Claim
28 words
The method of immunizing an animal against pseudorabies disease as in claim 96, wherein said animal is selected from the group consisting of swine, goats, sheep and cattle.
Claim 112
Dependent Claim
18 words
The method of immunizing an animal against pseudorabies disease as in claim 104, wherein said animal is swine.
Claim 113
Dependent Claim
18 words
The method of immunizing an animal against pseudorabies disease as in claim 104, wherein said animal is cattle.
Claim 114
Independent Claim
198 words
A method of immunizing an animal against pseudorabies disease comprising administering a pharmaceutically acceptable amount of a temperature-resistant pseudorabies virus which fails to produce any functional TK as a result of a deletion in the tk gene produced by a process comprising: (1) constructing a hybrid plasmid comprising a cloning vector and a DNA fragment of PRV containing substantially all of the PRV tk gene; (2) co-transfecting, in tk + host cells, the hybrid plasmid of step (1) with DNA from a temperature-resistant PRV tk - mutagen-induced mutant. (3) selecting, in tk - host cells, for PRV tk + from the virus produced in step (2); (4) deleting DNA sequences from the hybrid plasmid of step (1) such that less than substantially all of the PRV tk gene is present, while retaining PRV DNA sequences adjacent to each side of the deletion; (5) co-transfecting, in tk + host cells, PRV tk + DNA derived from the PRV tk + obtained in step (3) with the resulting hybrid plasmid of step (4); and (6) selecting, in tk - host cells, for PRV tk - from the virus produced in step (5) to produce temperature-resistant PRV tk - deletion mutants.
Claim 115
Independent Claim
198 words
A method of immunizing an animal against pseudorabies disease comprising administering a pharmaceutically acceptable amount of a temperature-resistant pseudorabies virus which fails to produce any functional TK as a result of a deletion in the tk gene produced by a process comprising: (1) constructing a hybrid plasmid comprising a cloning vector and a DNA fragment of PRV containing substantially all of the PRV tk gene; (2) co-transfecting, in tk + host cells, the hybrid plasmid of step (1) with DNA from a temperature-resistant PRV tk - mutagen-induced mutant. (3) selecting, in tk - host cells, for PRV tk + from the virus produced in step (2); (4) deleting DNA sequences from the hybrid plasmid of step (1) such that less than substantially all of the PRV tk gene is present, while retaining PRV DNA sequences adjacent to each side of the deletion; (5) co-transfecting, in tk + host cells, PRV tk + DNA derived from the PRV tk + obtained in step (3) with the resulting hybrid plasmid of step (4); and (6) selecting, in tk - host cells, for PRV tk - from the virus produced in step (5) to produce temperature-resistant PRV tk - deletion mutants.
Claim 116
Dependent Claim
24 words
The method of immunizing an animal against pseudorabies disease as in claim 107, wherein said deletion is about 10 to 1500 bp in size.
Claim 117
Dependent Claim
24 words
The method of immunizing an animal against pseudorabies disease as in claim 108, wherein said deletion is about 75 to 750 bp in size.
Claim 118
Dependent Claim
26 words
The method of immunizing an animal against pseudorabies disease as in claim 107, wherein said virus has the identifying characteristics of PRV(BUK-dl 3) (ATCC No. VR-2074).
Claim 119
Dependent Claim
40 words
The method of immunizing an animal against pseudorabies disease as in claim 107, wherein said cloning vector is selected from the group consisting of pBR322, pMB9, pBR325, pKH47, pBR328, pHC79, phage Charon 28, pKB11, pKSV-10, pMAR420 and oligo (dG)-tailed pBR322.
Claim 120
Dependent Claim
19 words
The method of immunizing an animal against pseudorabies disease as in claim 111, wherein said cloning vector is pBR322.
Claim 121
Dependent Claim
22 words
The method of immunizing an animal against pseudorabies disease as in claim 107, wherein said hybrid plasmid of step (1) is pBB-11.
Claim 122
Dependent Claim
33 words
The method of immunizing an animal against pseudorabies disease as in claim 107, wherein the PRV DNA sequences adjacent to each side of the deletion are at least about 400 bp in size.
Claim 123
Dependent Claim
25 words
The method of immunizing an animal against pseudorabies disease as in claim 107, wherein the resulting hybrid plasmid of step (4) is pBB-11 dl SacA26.
Claim 124
Dependent Claim
26 words
The method of immunizing an animal against pseudorabies disease as in claim 107, wherein said temperature-resistant PRV tk - mutagen-induced mutant is PRV(BUK-5A) (ATCC No. VR-2078).
Claim 125
Dependent Claim
26 words
The method of immunizing an animal against pseudorabies disease as in claim 107, wherein said PRV tk + DNA of step (5) is derived from PRV(BUK-5A-R1).
Claim 126
Dependent Claim
48 words
The method of immunizing an animal against pseudorabies disease as in claim 107, wherein said tk + host cells are selected from the group consisting of Rab-9, primary rabbit kidney cells, secondary rabbit kidney cells, monkey cells, human cells, human embryonic kidney cells and chick embryo fibroblast cells.
Claim 127
Dependent Claim
21 words
The method of immunizing an animal against pseudorabies disease as in claim 118, wherein said tk + host cells are Rab-9.
Claim 128
Dependent Claim
22 words
The method of immunizing an animal against pseudorabies disease as in claim 107, wherein said administering is conducted intranasally, intramuscularly or subcutaneously.
Claim 129
Dependent Claim
19 words
The method of immunizing an animal against pseudorabies disease as in claim 120, wherein said administering is conducted intramuscularly.
Claim 130
Dependent Claim
26 words
The method of immunizing an animal against pseudorabies disease as in claim 107, wherein said pharmaceutically effective amount is about 10 5 to 5×10 8 p.f.u.
Claim 131
Dependent Claim
26 words
The method of immunizing an animal against pseudorabies disease as in claim 122, wherein said pharmaceutically effective amount is about 10 6 to 10 7 p.f.u.
Claim 132
Dependent Claim
28 words
The method of immunizing an animal against pseudorabies disease as in claim 107, wherein said animal is selected from the group consisting of swine, goats, sheep and cattle.
Claim 133
Dependent Claim
18 words
The method of immunizing an animal against pseudorabies disease as in claim 124, wherein said animal is swine.
Claim 134
Dependent Claim
18 words
The method of immunizing an animal against pseudorabies disease as in claim 124, wherein said animal is cattle.
References Cited (Backward Citations)
US4049794A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-09-01 | 1990-03-03 | 1990-09-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-09-01 | 1994-03-03 | 1994-09-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-09-01 | 1998-03-03 | 1998-09-02 | $7700.00 | Window Closed / Lapsed |